Our Research and Development

Development of immunodiagnostic detection tools, targeting the identified disease specific biomarkers in blood, facilitates an indirect detection of the pathology in the PL joint with no need for invasive tissue sampling.

The main scientific challenge ahead of us is to accurately confirm the correlation between the biomarker found in joint tissue to biological signatures in blood, and relate this to patient outcome, pain, function scores and survival time of the prosthesis.

This effort is expected to generate a prototype diagnostic test that will aid the identification of patients with aseptic PL due to osteolysis, and further generate documentation on how this test may allow early identification of these patients. It is anticipated that this innovation will be implemented for clinical use to aid clinicians in identification of surgical candidates and at-risk patients, who need increased attention and specialized treatment to stop or delay PL. The innovation will further allow clinical trials of novel therapies in the field of prosthesis loosening.